A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

NCT01370148 | Completed Phase 1

• 1 other identifier: 087-CL-099
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.

Conditions

Liver Disease

Keywords

Pharmacokinetics; Protein Binding; Conivaptan; Vaprisol; Liver Disease; YM087

Outcome Measures

Primary Outcomes (1)

• Assess the effect of severe hepatic impairment on the plasma drug concentration of conivaptan through analysis of blood samples

  5 days

Study Arms (2)

Subjects with severe hepatic impairment

EXPERIMENTAL

Drug: conivaptan hydrochloride

Subjects with normal hepatic function

ACTIVE COMPARATOR

Drug: conivaptan hydrochloride

Interventions

conivaptan hydrochloride DRUG

Intravenous

Also known as: Vaprisol, YM087

Subjects with normal hepatic function; Subjects with severe hepatic impairment

Eligibility Criteria

• Age: 30 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with Normal Hepatic Function:
• Female subject must be either:
• post-menopausal prior to Screening, or
• premenarchal prior to Screening, or
• documented surgically sterile or post hysterectomy, or
• if of childbearing potential, must have a negative pregnancy test at Screening and must be using highly effective contraception prior to Screening and throughout the study period and for 28 days after final study drug administration
• Female subject must not be lactating and must not be breastfeeding at Screening or during the study period, and for 28 days after final study drug administration
• Female subject must not donate ova starting at Screening or during the study period, and for 28 days after final study drug administration
• Male subject must:
• be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 28 days after final study drug administration
• not donate sperm starting at Screening and throughout the study period, and for at least 28 days after final study drug administration
• Subject weighs at least 45 kg and has a body mass index between 18 and 40 kg/m2 inclusive
• The subject must have clinical laboratory test results within normal range, including liver function tests (LFTs)
• The subject must have had a normal 12-lead electrocardiogram (ECG)
• Hepatic Impaired Subjects:

You may not qualify if:

• Subjects with Normal Hepatic Function:
• Subject has a history of a clinically significant illness, and associated clinical symptoms, medical condition, or laboratory abnormality within past 3 months that would preclude participation in the study
• Subject has evidence of biliary obstruction or other causes of hepatic impairment
• Subject is known to have hepatitis or is a carrier of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or is known to be HIV positive or has HIV antibodies
• Subject has an impaired ability to sense thirst
• Subject has serum sodium less than 115mEg/L or greater than 140 mEg/L
• Subject has either a systolic blood pressure (BP) of greater than 140 mmHg or a diastolic BP of less than 56 mmHg
• Subject has taken any prescription or over-the-counter medications except for contraceptives, hormone replacement therapy and occasional acetaminophen, or alternative and complementary medicines within past 14 days
• Subject has a history of carcinoma, except for basal cell or cutaneous squamous cell carcinoma within past 5 years
• Subject drinks greater than 14 units of alcohol per week (Note: one unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)
• Subject has a history of substance abuse within past 6 months prior to Screening Visit or the subject tests positive at Screening or clinic admission for alcohol or drugs of abuse
• Subject is currently participating in another clinical trial or has received an investigational medication within past 30 days
• Subject is known to have hypersensitivity to conivaptan or its derivatives
• Subject has had a blood transfusion or donated/lost more than 550ml of blood within past 8 weeks
• Subject is incapable of being compliant with the protocol

Sponsors & Collaborators

• Cumberland Pharmaceuticals: lead

Study Sites (3)

Advanced Clinical Research Institute

Anaheim, California, 92801, United States

Location

DaVita Clinical Research

Lakewood, Colorado, 80228, United States

Location

Orlando Clinical Research

Orlando, Florida, 32809, United States

Location

MeSH Terms

Conditions

Liver Diseases

Interventions

conivaptan

Condition Hierarchy (Ancestors)

Digestive System Diseases

Study Officials

• Art Wheeler, MD

  Cumberland Pharmaceuticals, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2011
• First Posted: June 9, 2011
• Study Start: April 1, 2011
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: May 2, 2014

Record last verified: 2014-04

Locations

US (3)